Pure ductal adenocarcinoma of the prostate (dPC) is thought to be found in just 0.4 to 0.8 percent of men who get diagnosed with prostate cancer each year. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adenocarcinoma, damage, DNA, ductal, homologous, mismatch, prostate, repair, sequencing | Leave a comment »
Regular readers of the medical science literature will be very conscious of the emphasis on genomic analysis of tumor specimens as a way to try to “personalize” treatment of cancers of many types — prostate cancer very specifically included. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: DNA, genome, individualized, medicine, personalized, sequencing, Treatment | 10 Comments »
A paper in the International Journal of Cancer offers information on the sequencing of cabazitaxel (CAB) and abiraterone acetate (ABI) in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cabazitaxel, outcome, risk, sequencing, Treatment | Leave a comment »
A paper to be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago is entitled, “A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results.” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, deprivation, recurrence, sequencing, sipuelucel-T | 2 Comments »
There is an interesting report on the OncLive web site of a lecture by Dr. Robert Dreicer given just a few weeks ago and dealing with the sequential and combination use of new agents like abiraterone acetate, enzalutamide and others for the treatment of advanced and progressive forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, combination, enzalutamide, radium-223, sequencing, sipuleucel-T | 14 Comments »
A paper in the Annals of Oncology suggests that treatment with abiraterone acetate may induce a loss of effectiveness of docetaxel-based chemotherapy and that men with metastatic, castration resistant prostate cancer (mCRPC) who do not respond to abiraterone acetate will also not respond to docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, docetaxel, enzalutamide, mCRPC, resistance, sequencing | 4 Comments »
The January 2012 issue of Oncology contains an open access, full-text article on the future sequencing of the recently approved and potentially new drugs that are or should soon be available for the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, drugs, new, sequencing | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 